AstraZeneca Pharma India Plans To Sell Bengaluru Manufacturing Plant. (Photo: Reuters)
AstraZeneca Pharma India will place the manufacturing website on the market in a totally operational method and start a seek for a purchaser who may also act as CMO for its merchandise
AstraZeneca Pharma India on Thursday stated it intends to exit the manufacturing website in Bengaluru as a part of AstraZeneca’s ongoing strategic evaluate of its international manufacturing and provide community.
The firm stays dedicated to advance entry to progressive medicines in India, with a transparent ambition to be pioneers in science, lead in specialist illness areas, and rework affected person outcomes, AstraZeneca Pharma India stated in a regulatory submitting on Thursday.
“As a part of AstraZeneca’s ongoing strategic review of its global manufacturing and supply network, the company intends to exit the manufacturing site in Bangalore, in due course,” it added.
The firm will place the manufacturing website on the market in a totally operational method and start a seek for a purchaser who may also act as a contract manufacturing organisation (CMO) for its merchandise presently manufactured or packaged on the website, topic to receipt of vital statutory approvals, the drug agency stated.
The firm is totally cognisant of the impression this alteration can carry and its first accountability can be in the direction of its workers and assembly the wants of its sufferers by guaranteeing an uninterrupted provide of medicines, it added.
AstraZeneca Pharma India’s Bengaluru facility is without doubt one of the 9 international websites that assist the design and conduct of scientific trials, monitoring of security and efficacy and different regulatory administration required throughout a product’s lifecycle. AstraZeneca Pharma India, a subsidiary of AstraZeneca Plc, UK, was established in 1979 and is headquartered in Bengaluru.
